Best Chemical Plant Berkeley Near Me

4worldlovers: Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer issues new senior bonds with a volume of 3 billion euros

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

Bayer to invest a total of 60 million euros in its Ukrainian seed production site

Bayer pledges to help tackle global water crisis with new water strategy

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

Bayer to distribute pheromone-based biological crop protection solutions from M2i Group

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Bayer recognized as leader on climate change for fifth consecutive year

Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros

Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity

Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

Bayer completes sale of its Environmental Science Professional business to Cinven

Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer supports demining in Ukraine with donation to non-profit “Fondation suisse de déminage”

Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Bayer to sell men’s health product Nebido to Grünenthal

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology

Bayer expands Radiology Business into AI Market with Calantic Digital Solutions

Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development

Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

Bayer’s Vividion emerging as significant player in San Diego biotech hub